clients.
overview
Achaogen
Achaogen is dedicated to addressing serious medical needs caused by the development of bacterial resistance to antibiotics.
Acucela
Acucela is leveraging promising science in visual cycle modulation to develop new methods for treating blinding eye diseases that affect tens of millions of people worldwide.
Alnara Pharmaceuticals, Inc.
Alnara Pharmaceuticals, Inc. is dedicated to developing novel protein therapeutics for the treatment of metabolic diseases. The company's innovative approach focuses on designing effective protein therapies that can be orally delivered directly to the gastrointestinal tract without being absorbed into the bloodstream.
ARIAD Pharmaceuticals, Inc.
ARIAD (NASDAQ: ARIA) is a Cambridge, Massachusetts-based biotechnology company focused on cancer. We are a cohesive team of talented people from diverse backgrounds with a shared vision: We seek to transform the lives of patients with breakthrough cancer medicines. This is our purpose. This is our passion. This is our promise.
AVEO Pharmaceuticals, Inc.
AVEO is a late-stage biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics. AVEO's proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets and therapies.
Dicerna Pharmaceuticals
Dicerna Pharmaceuticals is a private, venture-backed biopharmaceutical company developing novel therapeutic agents in multiple therapeutic areas based on its proprietary Dicer Substrate Technology™, which triggers RNA interference (RNAi) in a potent and specific manner.
Eleven Biotherapeutics
Eleven Biotherapeutics is a biopharmaceutical company focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics.
Gemin X Pharmaceuticals
Gemin X Pharmaceuticals is dedicated to the discovery, development and commercialization of novel, targeted cancer therapeutics to improve the lives of patients.
GI Dynamics
GI Dynamics is defining important new options for people who need to take control of their weight and their health. The EndoBarrier™ technology is designed to modify metabolic pathways by lining a portion of the gastrointestinal tract. This is done via an endoscopic procedure. This noninvasive approach may represent a significant advancement over traditional pharmaceutical and surgical interventions.
Infinity Pharmaceuticals
The mission of Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) is to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions. We have built a pipeline of innovative product candidates for multiple cancer indications, all of which represent proprietary applications of our expertise in small molecule drug discovery and development.
Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging is a worldwide leader in medical imaging, with headquarters in North Billerica, Massachusetts, and nearly 700 employees worldwide with offices in Puerto Rico, Canada, and Australia.
NiTi Surgical Solutions
NiTi™ Surgical Solutions has developed the first major advance in tissue reconnection for gastrointestinal surgery in more than 30 years. NiTi's proprietary technology represents a breakthrough in natural healing with tissue-sparing, uniform Compression Anastomosis.
Osteotech, Inc.
Osteotech, Inc. (NASDAQ: OSTE) is a global leader in the processing of human bone and connective tissue for transplantation and an innovator in the development, manufacturing and marketing of biologic, biomaterial and device systems for musculoskeletal surgery. With a particular focus on spinal, trauma, and total joint revision procedures, the Company's current and development-stage technologies address needs within numerous musculoskeletal disciplines.
Predictive Biosciences
Leveraging its portfolio of patented biomarkers and clinical algorithms, Predictive Biosciences is a leader in developing highly accurate, noninvasive diagnostic products for informed cancer management, resulting in actionable information for personalized diagnostic follow-up and more effective utilization of gold-standard diagnostic interventions.
http://www.predictivebiosci.com
PTC Therapeutics, Inc.
PTC Therapeutics, Inc. (PTC) is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes.
SEQUENOM, Inc.
SEQUENOM (NASDAQ: SQNM) is committed to providing the best genetic analysis products that translate genomic science into superior solutions for biomedical research, agricultural applications, molecular medicine and non-invasive prenatal diagnostics research, and potentially, clinical utility.
Sirtris, a GSK company
Sirtris is focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, such as Type 2 Diabetes. Sirtris' research focus is on modulating the sirtuins, a recently discovered class of enzymes involved in the aging process.
Tengion
Tengion is a leader in the field of regenerative medicine. We are developing new human organs and tissues that are derived from a patient's own cells.
Tokai Pharmaceuticals
Tokai Pharmaceuticals is a privately held U.S. biopharmaceutical company based in Cambridge, MA, focused on developing new treatments for prostate cancer. The company's lead drug candidate, TOK-001, is currently being studied in patients with castration resistant prostate cancer (CRPC) as part of the ARMOR clinical development program. TOK-001 is a small molecule, oral drug that disrupts the growth and survival of cancer cells by attacking three specific targets in the prostate cancer tumor. This approach represents a new and proprietary triple mechanism of action for the treatment of prostate cancer.
VBL Therapeutics
VBL Therapeutics is an innovative, clinical stage biotechnology company committed to the development of novel treatments for immuno-inflammatory diseases and cancer.
Vivus
VIVUS (NASDAQ: VVUS) is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health.
Zafgen, Inc.
Zafgen is the world's first biopharmaceutical company dedicated to developing novel obesity therapeutics that directly target and shrink fat tissue to help the body regain and sustain a lean, healthy state.
